Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuACT: DN24-02 in high risk HER2+ urothelial carcinoma
NCT01353222Phase 2Terminated
- Sponsor
- Dendreon
- Start
- Jun 2011
- Primary completion
- Jul 2015
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of DN24-02 in urothelial carcinoma (UC), sponsored by Dendreon. Started Jun 2011; status: terminated.
02
Drugs
DN24-02
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01353222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01353222.